BergenBio Fundamentale Forhold (BGBIO)

[ufo]

Selskapet sitter jo på veldig mye kapital allerede.

Hva ligger bak denne meldingen?

Hvorfor ha muligheten til å kapitalisere ytterliggere på så kort tid?

Kan det være positive faktorer som seiler opp nå som tilsier at selskapet trenger ytterliggere kapital for å kunne realisere?
Har det skjedd noe positivt under korona-studiet?

[Hayen]

20% åpner iallefall opp for at f. eks Merck kan kjøpe seg inn i selskapet.

[larsmkn]

20% åpner iallefall opp for at f. eks Merck kan kjøpe seg inn i selskapet.

Viktig poeng. De har vel ikke muligheten til at store selskaper kan kjøpe seg inn uten denne 20% de nå vil ha. Det vil da gi flere strategiske muligheter fremover.

[Mykle]

Noe av hypen i BGBio var nok relatert til at selskapet ikke kunne kjøre flere emisjoner før etter at alt rundt korona var avklart og 2020 var ferdig.

Er dette en hype som driver aksjen nå?
Hadde du sagt covid 19 hype, så ok. Kommer det en ny emisjon slik du tegner bildet vil det være på langt høyere kurs mot en partner, eller at det ligger noe annet uventet i pipen

[Timm]

3 av BGBIO’s studier har endringer i test-protokollen idag.

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With...

Endret “Primary Completion” fra December 2019 til December 2022
Endret “Study Completion” fra December 2020 til December 2022

A First-time-in-human Study of BGB149 - Full Text View - ClinicalTrials.gov

Endret status til Completed

Evaluating the Efficacy and Safety of Bemcentinib in Patients With...

Endret fra “Not yet recruting” til “Recruting” for 3 av lokasjonene

[vcp]

Rosinen i pølsen

[Shattering84]

Hvordan er den rosinen relevant? Noe som ble ferdigstilt i mars?

[vcp]

Hva?

[tekdude]

hva er dette? http://www.accord.scot/sites/default/files/ACCORD%20Guidance%20for%20Restarting_Commencing%20Non-COVID-19%20Clinical%20Research%20v2.0.pdf

[eiken]

De fleste studier er stoppet.covid-19 prioriteres.

[Timm]

Det gjelder å ikke blande sammen de to ACCORD begrepene i England.

ACCORD - ACcelerating COVID-19 Research & Development platform

ACCORD - Academic and Clinical Central Office for Research and Development

Dette brevet er fra sistnevnte (det sentrale kontoret for akademisk og klinisk forskning og utvikling) og beskriver hvordan man skal kunne restarte annen type klinisk forskning igjen som IKKE har med COVID-19 å gjøre (Non-COVID-19 Clinical Research). Mye av annen forskning er jo lagt på is i det siste.

BGBIO er med på førstnevnte, en studie som forvirrende nok også heter ACCORD, men dette er jo COVID-19 forskning og dette brevet har derfor ikke noe med BGBIO’s prosjekt å gjøre.

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @vcp (768 likes)

Hva er dette ‍♂

2. @larsmkn (662 likes)

BergenBio Småprat (BGBIO)

For de som lurer på hva BerGenBio egentlig holder med på til vanlig.

3. @Mykle (431 likes)

Det er tydelig at de klamrer seg til de halmstråene de har. Det faktum at en et studie publisert i Lancet blir helt satt til side vekker sterk grunn til mistanke.

Resten av topp 10:

4. @ezPappi (347 likes)

5. @Savepig (318 likes)

6. @Flottesen (299 likes)

7. @Ekornet (230 likes)

8. @Timm (227 likes)

9. @Magnus1 (222 likes)

10. @Evilfreud (180 likes)

Gratulerer!

[TekBot]

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

Bergen, Norway - 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that dosing has commenced in the UK
…

Vis børsmeldingen

Government-backed Phase II clinical trial assessing bemcentinib in hospitalised
COVID-19 patients.

Bemcentinib was selected as the first candidate to be tested as part of the
ACcelerating COVID-19 Research & Development platform (ACCORD) study, launched
by the Department of Health and Social Care (DHSC) and UK Research and
Innovation (UKRI) on 28[th] April 2020. ACCORD brings together a single, UK
-wide clinical trial platform to rapidly test potential drugs through early
stage clinical trials and feed them into the UK’s large-scale COVID-19 studies.

The first patient has been dosed with bemcentinib at the University Hospital
Southampton NHS Foundation Trust. The study is open in a further seven sites
across the UK. The Phase II study will recruit 120 subjects in total, assessing
the safety and efficacy of bemcentinib as an add-on therapy to standard of care
(SoC) in 60 hospitalised COVID-19 patients with a further 60 control group
patients receiving SoC.

BerGenBio anticipates that top line data will readout later in the summer. Data
will be open source and freely available to enable global knowledge sharing and
collaboration. If positive results are seen, bemcentinib will advance rapidly
into the large-scale Phase III trials in the UK.

The study is fully funded by the DHSC and UKRI and is being managed by clinical
research company IQVIA. Drug material and other trial resources will be provided
by BerGenBio.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are
delighted that dosing has commenced with bemcentinib in the ground-breaking
ACCORD study and we hope that patients will swiftly start to see benefits.
Initiating this clinical trial in such short order is the result of tremendous
teamwork between my colleagues at BerGenBio and the teams at IQVIA and UHS,
among many others. This illustrates exactly what can be achieved when we all
work together and focus on delivering the best experimental drug candidates to
patients that so urgently need them. We look forward to providing results as
soon as is practically possible and very much hope our drug can fulfil the aims
of the study and be used to treat thousands of COVID-19 patients worldwide.”

Professor Tom Wilkinson, ACCORD clinical academic lead based at the National

Institute for Health Research (NIHR) Southampton Biomedical Research Centre,
said: “The ACCORD platform is allowing us to rapidly test potential new
treatments in response to the COVID-19 emergency. This unique national platform
for developing COVID-19 drug candidates will access the world-class expertise
and resources of the NIHR Respiratory Translational Research Collaboration and
allied centres nationwide. We believe this programme will be key to developing
effective new treatments and are delighted to see the first candidate,
bemcentinib, enter the clinic today.”

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers and
COVID-19 infections. The company’s proprietary lead candidate, bemcentinib, is a
potentially first-in-class selective AXL inhibitor in a broad Phase II oncology
clinical development programme focused on combination and single agent therapy
in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking
anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In
parallel, BerGenBio is developing companion diagnostic tests to identify those
patient populations most likely to benefit from bemcentinib or tilvestamab: this
is expected to facilitate more efficient registration trials and support a
precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

For more information, please contact

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 7780 600290

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

Bergen, Norway - 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that dosing has commenced in the UK
…

Vis børsmeldingen

Government-backed Phase II clinical trial assessing bemcentinib in hospitalised
COVID-19 patients.

Bemcentinib was selected as the first candidate to be tested as part of the
ACcelerating COVID-19 Research & Development platform (ACCORD) study, launched
by the Department of Health and Social Care (DHSC) and UK Research and
Innovation (UKRI) on 28[th] April 2020. ACCORD brings together a single, UK
-wide clinical trial platform to rapidly test potential drugs through early
stage clinical trials and feed them into the UK’s large-scale COVID-19 studies.

The first patient has been dosed with bemcentinib at the University Hospital
Southampton NHS Foundation Trust. The study is open in a further seven sites
across the UK. The Phase II study will recruit 120 subjects in total, assessing
the safety and efficacy of bemcentinib as an add-on therapy to standard of care
(SoC) in 60 hospitalised COVID-19 patients with a further 60 control group
patients receiving SoC.

BerGenBio anticipates that top line data will readout later in the summer. Data
will be open source and freely available to enable global knowledge sharing and
collaboration. If positive results are seen, bemcentinib will advance rapidly
into the large-scale Phase III trials in the UK.

The study is fully funded by the DHSC and UKRI and is being managed by clinical
research company IQVIA. Drug material and other trial resources will be provided
by BerGenBio.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are
delighted that dosing has commenced with bemcentinib in the ground-breaking
ACCORD study and we hope that patients will swiftly start to see benefits.
Initiating this clinical trial in such short order is the result of tremendous
teamwork between my colleagues at BerGenBio and the teams at IQVIA and UHS,
among many others. This illustrates exactly what can be achieved when we all
work together and focus on delivering the best experimental drug candidates to
patients that so urgently need them. We look forward to providing results as
soon as is practically possible and very much hope our drug can fulfil the aims
of the study and be used to treat thousands of COVID-19 patients worldwide.”

Professor Tom Wilkinson, ACCORD clinical academic lead based at the National

Institute for Health Research (NIHR) Southampton Biomedical Research Centre,
said: “The ACCORD platform is allowing us to rapidly test potential new
treatments in response to the COVID-19 emergency. This unique national platform
for developing COVID-19 drug candidates will access the world-class expertise
and resources of the NIHR Respiratory Translational Research Collaboration and
allied centres nationwide. We believe this programme will be key to developing
effective new treatments and are delighted to see the first candidate,
bemcentinib, enter the clinic today.”

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers and
COVID-19 infections. The company’s proprietary lead candidate, bemcentinib, is a
potentially first-in-class selective AXL inhibitor in a broad Phase II oncology
clinical development programme focused on combination and single agent therapy
in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking
anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In
parallel, BerGenBio is developing companion diagnostic tests to identify those
patient populations most likely to benefit from bemcentinib or tilvestamab: this
is expected to facilitate more efficient registration trials and support a
precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

For more information, please contact

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 7780 600290

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

Bergen, Norway - 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that dosing has commenced in the UK
…

Vis børsmeldingen

Government-backed Phase II clinical trial assessing bemcentinib in hospitalised
COVID-19 patients.

Bemcentinib was selected as the first candidate to be tested as part of the
ACcelerating COVID-19 Research & Development platform (ACCORD) study, launched
by the Department of Health and Social Care (DHSC) and UK Research and
Innovation (UKRI) on 28[th] April 2020. ACCORD brings together a single, UK
-wide clinical trial platform to rapidly test potential drugs through early
stage clinical trials and feed them into the UK’s large-scale COVID-19 studies.

The first patient has been dosed with bemcentinib at the University Hospital
Southampton NHS Foundation Trust. The study is open in a further seven sites
across the UK. The Phase II study will recruit 120 subjects in total, assessing
the safety and efficacy of bemcentinib as an add-on therapy to standard of care
(SoC) in 60 hospitalised COVID-19 patients with a further 60 control group
patients receiving SoC.

BerGenBio anticipates that top line data will readout later in the summer. Data
will be open source and freely available to enable global knowledge sharing and
collaboration. If positive results are seen, bemcentinib will advance rapidly
into the large-scale Phase III trials in the UK.

The study is fully funded by the DHSC and UKRI and is being managed by clinical
research company IQVIA. Drug material and other trial resources will be provided
by BerGenBio.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are
delighted that dosing has commenced with bemcentinib in the ground-breaking
ACCORD study and we hope that patients will swiftly start to see benefits.
Initiating this clinical trial in such short order is the result of tremendous
teamwork between my colleagues at BerGenBio and the teams at IQVIA and UHS,
among many others. This illustrates exactly what can be achieved when we all
work together and focus on delivering the best experimental drug candidates to
patients that so urgently need them. We look forward to providing results as
soon as is practically possible and very much hope our drug can fulfil the aims
of the study and be used to treat thousands of COVID-19 patients worldwide.”

Professor Tom Wilkinson, ACCORD clinical academic lead based at the National

Institute for Health Research (NIHR) Southampton Biomedical Research Centre,
said: “The ACCORD platform is allowing us to rapidly test potential new
treatments in response to the COVID-19 emergency. This unique national platform
for developing COVID-19 drug candidates will access the world-class expertise
and resources of the NIHR Respiratory Translational Research Collaboration and
allied centres nationwide. We believe this programme will be key to developing
effective new treatments and are delighted to see the first candidate,
bemcentinib, enter the clinic today.”

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers and
COVID-19 infections. The company’s proprietary lead candidate, bemcentinib, is a
potentially first-in-class selective AXL inhibitor in a broad Phase II oncology
clinical development programme focused on combination and single agent therapy
in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking
anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In
parallel, BerGenBio is developing companion diagnostic tests to identify those
patient populations most likely to benefit from bemcentinib or tilvestamab: this
is expected to facilitate more efficient registration trials and support a
precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

For more information, please contact

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 7780 600290

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Fornybar]

Data
will be open source and freely available to enable global knowledge sharing and
collaboration.

Verden kan åpne seg raskere enn vi tror. Veldig spennende og en fantastisk gratissjanse for et norsk selskap.

[Kjell_Makrell]

Dette var en fin melding å få på en tirsdag morra

[Evilfreud]

Arctic

• BERGENBIO: FIRST PATIENT INCLUDED

1. Bemcentinib: first drug candidate to be fasttrack in UK initiative (ACCORD)
2. The phase 2 study will include 120 patients (60 on bemcentinib and 60 placebo)
3. First patient included. Result expected aug/sep, then potential fast initiation of phase 3
4. Potential approval and sales from Q4/20

[Markusf]

Når kan vi forvente oppdatert kursmål fra Arctic?

[Fornybar]

Salg i 4Q20?